The small molecule BRAF inhibitors (BRAFi), vemurafenib, dabrafenib, and encorafenib, are used in the treatment of human patients with BRAF-mutant melanoma, non-small cell lung cancer, anaplastic thyroid cancer, glioma, and colorectal cancer [24,25,26,27,28], as they selectively target BRAF and thus interfere with the MAPK signalling pathway that regulates the proliferation and survival of the tumour cells (Figure 2d). This evidence concerns the gene BRAF and colorectal cancer.